Translated to Russian by E.S. Kamyshova, edited by E.V. Zakharova Translation initiated by Russian Dialysis Society and approved by ERBP

New-onset diabetes after transplantation (NODAT) is a well-known complication of immunosuppressive therapy after transplantation, being a risk factor of allograft survival. NADAT is well-studied in the adult population, but significantly less studied in the pediatric one. Aim. To determine the frequency and factors influencing the development of NODAT in children and its impact on the survival rate of the allograft. Materials and Methods. During 5 year period (2008-2013) we analyzed genealogical data, blood glucose, cholesterol, triglycerides, urea, creatinine, CMV infection using specific PCR before and after transplantation, as well as mass-growth parameters, BMI calculation in 164 children with kidney allograft. Results. The incidence of diabetes in children with kidney allograft was 9.76%. Among the risk factors NODAT we identified a genetic predisposition to diabetes, metabolic syndrome (р=0.042 и р=0.048), high BMI (р=0.009). We also demonstrated that diabetes in children developed after kidney transplantation reduces allograft survival.

Aim. The purpose of our research was the determination of cystatin C (СysC) and interleukin-18 level alongside with the known AKI markers: serum creatinine, GFR, examination at three-stages of treatment of inpatient children with lymphomas: at original admission of a child to the inpatient department, on the background of intensive polychemotherapy and upon the completion of therapy. Materials and methods. 40 patients with newly diagnosed lymphoma in the period from 01/2008 till 01/2014 were included into the study. Results. The serum creatinine level for children with lymphomas at the background of chemotherapy averaged 0.88±0.19 mg%, and was significantly higher than before the start and after the completion of intensive therapy. The level of СysC in blood before the therapy was 0.92±0.22 mg/l. At the background of intensive treatment it increased to 1.36±0.48 mg/l, and remained at the level of 1.30±1.10 mg/l when the intensive therapy was completed. The average level of interleukin-18 in serum of patients with lymphomas was 525.02±106.44 pg/ml before therapy. At the background of intensive therapy it increased to 963±196.14 pg/ml with the subsequent decrease to 759±277.63 pg/ml during the period of remission of the main disease. Conclusion. Thus, we have detected an increase in СysC and interleukin-18 levels for children with lymphomas at the background of intensive polychemotherapy compared to the periods before and after the treatment. These indicators could be used for prediction of development of toxic AKI.